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number of patients are seen at smaller, non-specialized hospitals, who are experienced in
cardiac catheterization and are interested to offer TAVI to their patients but lack the
structural requirements and experience. We aimed to assess whether a collaborative
performance of TAVI by external interventional cardiologists together with an experi-
enced TAVI team may offer an opportunity to safely treat these patients, thereby
overcoming the inherent learning curve by so-called “on-site proctoring”.
Methods: 490 patients were treated by TAVI at our university hospital since 2005, 282
using TF access. 41 additional TF-TAVI cases were performed by two external
interventionalists together with our institutional heart team. Procedural safety and
outcome was analyzed and compared to our own TF experiences.
Results: In these 41 patients, TF-TAVI could be performed with procedural, 30-day and
1-year mortality rates of 2, 7 and 10%. These rates are similar to our own most recent
results (last tertile: 1.2, 8 and 12%). 9 procedural complications occurred: 1 wire
perforation with surgical conversion and procedural death, 1 major stroke, 1 coronary
occlusion, 5 major vascular complications, 1 minor stroke. In addition to the procedural
death, the patient with the major stroke and one vascular complication patient with
life-threatening bleeding died within 30 days despite initially successful, interventional
management. The other 4 pts. with vascular complications were treated by covered-stent
implantation and recovered without sequelae, and the coronary occlusion was managed by
immediate stentimplantation. Of note, the amount of vascular complications (12%) was
higher than in our latest patient tertile (7%) but still lower than in our initial tertile (33%).
Conclusions: TF-TAVI can be performed with good results by external interventionalists
in collaboration with an institutional heart team at a specialized TAVI-center. Our
observation also supports the concept of “on-site” proctoring for new TAVI operators,
especially regarding complication management.
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Background: Significant PAR has been shown to occur in 20% of pts. undergoing TAVI
and associatd with increased cardiovascular mortality. Pathophysiologially, this may be
explained by a reduced DPTI:SPTI, which is found in severe aortic stenosis. We sought
to evaluate the already established cut-off value of 0.7 for assessing relevance of PAR.
Methods: Data of 167 consecutive TAVI pts. were analysed (ES: 79, MCV: 88), and
PAR was graded angiographically. DPTI:SPTI was calculated based on planimetric
integration of the diastolic area (diastolic pressure time indexDPTI) and the systolic area
(systolic pressure time indexSPTI) (Fig. A).
Results: PAR was observed in 113 (67%) pts. 89 (78.8%) showed mild, 21 (18.6%)
moderate and 3 (2.7%) moderate-to-severe PAR. Cardiovascular mortality at 30 days and
1-year was significantly increased in pts with moderate/moderate-to-severe PAR com-
pared to those with no/mild PAR (50vs4.5% and 71vs6.9%, p0.05). The already
established cut-off value of 0.7 for DPTI:SPTI could be confirmed as an important
quantitative parameter for prediction of cardiovascular mortality (Fig. B). 18 of the 24 pts.
with moderate/moderate-to-severe PAR had a DPTI:SPTI  0.7.
Conclusions: A DPTI:SPTI 0.7 is highly predictive for cardiovascular mortality in the
assessment of paravalvular PAR after TAVI. Though somewhat complex to calculate
compared to previously proposed parameters (e.g. difference between diastolic aortic and
LV enddiastolic pressure,it is independent from heart rate and reflects myocardial
perfusion impairment, which offers a pathophysiological explanation for the increased
mortality.
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Background: There are several risk-stratification tools for cardiac surgery including
aortic valve replacement, but similar models are lacking for transcatheter aortic valve
replacement (TAVR).
Methods: We retrospectively examined the clinical features and course of 45 patients
who underwent transcatheter aortic valve replacement (TAVR) with the Edwards-Sapien
valve for critical aortic stenosis at our center. All were inoperable for surgical valve
replacement. Hospital length of stay (LOS) was calculated from the date of TAVR to the
date of discharge and was expressed as mean SD. Pre-operative clinical variables were
entered in a Cox-hazard proportional model for LOS. Among these variables, the frailty
index was scored with 1 point assigned for each: serum albumin3.5 mg/dl, in-ability to
independently perform at least 4 of 6 Katz activities of daily living, inability to walk 5
meters in less than 7 sec, and grip strength  18 kg. Patients with  3 points were
considered frail.
Results: The mean LOS for all 45 patients was 9.9  6.9 days. Multivariate predictors
of length of stay are illustrated in the table. A total of 22 (49%) were categorized as frail
as per our index definition. Mean LOS was 12.18.4 days among frail patients vs 7.7 
4.0 days among non-frail patients (p0.029).
Parameter OR OR (95%CI) p value
Age (yrs) 2.071 1.221–3.332 0.005
Frailty 5.910 3.730–10.471 0.015
Pre-operative Hemoglobin (g/dl) 0.048 0.015–0.916 0.041
Pre-operative Creatinine (mg/dl) 0.001 0.000–0.006 0.008
Pre-operative Ejection fraction 1.350 0.796–1.965 0.330
Underlying Moderate –Severe lung
disease
0.178 0.030–1.067 0.059
Conclusions: Our study suggests that frailty is not only a marker for inoperability for
surgical aortic valve replacement, but is also predictive of prolonged recovery among
patients undergoing transcatheter aortic valve replacement for critical aortic stenosis. This
information can be used not only for optimal patient selection but also for counseling
patients about realistic post-operative goals and expectations.
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Background: B-type natriuretic peptide (BNP) is released in response to increased
myocardial wall stress and its levels are known to increase in diastolic and systolic heart
failure. Heart failure related to severe aortic stenosis is expected to improve after valve
replacement. We examined the relationship between BNP and survival after Transcatheter
Aortic Valve Replacement (TAVR).
Methods: We retrospectively reviewed 48 patients who underwent TAVR and had NT
proBNP measured 1 day before (preBNP) and 30 days after TAVR (postBNP). Vital and
clinical status was assessed 1, 6, 12, and 24 months after TAVR. DeltaBNP was
calculated ( postBNP – preBNP). Death from any cause was the primary outcome. We
calculated a hazard ratio (HR) of mortality using the Cox proportional multivariate model.
Results: The median deltaBNP was ()2161 pg/ml (Range: decrease of ()17,481
pg/ml to increase of (	)17,754 pg/ml). This median value divided the patients into those
with (n24) or without (n24) deltaBNP decrease greater than ()2000 pg/ml. PreBNP
did not correlate with survival (p0.264), but a BNP decrease of more than 2000 pg/ml
was strongly associated with survival (HR  0.15, CI (0.05 - 0.49) p0.01); (Figure 1).
TUESDAY, OCTOBER 23, 8:00 AM–10:00 AMwww.jacc.tctabstracts2012.com







Conclusions: In this series of patients undergoing TAVR and having sequential BNP
measurements, baseline BNP did not predict survival, but BNP decreasing by more than
2000 pg/ml 30 days after TAVR was a strong predictor of survival.
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Background: To serve as comparative data for percutaneous replacement, the purpose of
this study was to characterize the historical outcomes for aortic and mitral valve
replacement surgery in a large, nationally representative patient population.
Methods: Patients undergoing aortic or mitral valve replacement were identified from the
5% national Medicare data (1997-2009) using ICD-9-CM codes 35.21 to 35.24. The
subsequent rates of mortality, mechanical complications, infection, and valve re-
implantation/reoperation, and infective endocarditis were evaluated. Hospitalization
charges and reimbursements (in Jan 2011 dollars) for the index procedure were also
assessed.
Results: The patient cohort included 12,202 aortic bioprosthesis, 9,757 aortic
mechanical valves, 3,222 mitral bioprosthesis, and 4,401 mitral mechanical
valves. The ten-year Kaplan-Meier mortality, mechanical complication, infection,
re-implantation/reoperation, and infective endocarditis rates for aortic biopros-
thesis were 64.4%, 4.41%, 4.54%, 1.50%, and 8.34%, respectively, and for aortic
mechanical valves were 63.9%, 5.23%, 4.71%, 1.84%, and 9.08%, respectively.
The corresponding ten-year Kaplan-Meier rates for mitral bioprosthesis were
74.8%, 8.02%, 6.29%, 2.81%, and 12.90%, respectively, and for mitral mechan-
ical valves were 64.7%, 7.60%, 6.06%, 2.87%, and 12.24%, respectively. The
average hospitalization reimbursements for procedures involving aortic biopros-
theses, aortic mechanical valves, mitral bioprostheses, and mitral mechanical
valves were $54.3k, $54.6k, $64.1k, and $62.2k, respectively.
Conclusions: The crude risk of mortality and complications, as well as payer costs, were
found to be higher for mitral valve replacements compared with aortic valve replace-
ments. This study provides baseline data for evaluating the comparative effectiveness of
percutaneous valve replacement to “traditional” approaches, especially since the percu-
taneous approach may have inherently different levels of performance or expanded
indications.
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Background: Long-standing aortic stenosis (AS) causes left ventricular (LV)
dysfunction, which may improve after trans-catheter aortic valve implantation
(TAVI). The LV subendocardium is composed of longitudinal fibres which are
highly sensitive to ischaemia caused by high LV filling pressures. Measurement
of long axis systolic amplitude is an easy measure of subendocardial function. The
aim of this study was to assess the nature of subendocardial abnormalities in AS
and their response to TAVI.
Methods: We studied 46 consecutive patients (age 827 years) with severe AS
but no flow-limiting coronary artery disease, one week before and 6 months after
TAVI. LV ejection fraction (LVEF) was calculated using Simpsons biplane
methods. LV subendocardial dysfunction was studied from long axis M-mode
amplitude at the lateral, septal, and posterior sites. Systolic amplitide was
measured as displacement of the mitral ring between the q wave of the ECG to
aortic valve closure. Incoordination (post-ejection shortening: PES) was measured
as amplitude of further inward motion after aortic valve closure. LV diastolic
function was assessed by mitral filling velocities (early diastolic: E wave, and late
diastolic: A wave). Averaged values for lateral, septal, and posterior sites are
presented, and values were compared to 17 normal controls.
Results: In controls, LVEF was 657%, long axis systolic amplitude and velocity
were 143mm and 72cm/s, there was no PES, and E:A ratio was 1.00.3. In
patients before TAVI, LVEF, long axis systolic amplitide and velocities were
lower than controls (4619%, 6.52.1mm, 4.11.9cm/s respectively), PES was
present (31mm) and E:A was higher than controls (3.34.6, all p0.01). After
TAVI, LVEF did not change (4917%), but long axis systolic amplitide and
velocities increased (to 9.22.3mm, and 6.72.1cm/s); PES increased (to
52mm) and E:A ratio fell (to 2.11.4).
Conclusions: Relief of AS following TAVI causes improvement in LV subendo-
cardial function manifest as increased long axis systolic amplitude and velocity.
However reduction in LV-EDP also permits appearance of incoordination, with
associated abnormal diastolic function, that may require exclusion of epicardial
coronary obstruction.
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Background: Advances in cardiovascular care has a significant impact on changing the
landscape of valvular heart disease. Balloon aortic valvuloplasty (BAV) considered to be
of palliative role become of essential importance in the era of TAVI. Patients with severe
aortic stenosis and poor surgical candidacy not yet qualifying for TAVI still require BAV
as a main therapeutic tool. The hemodynamic stress of BAV on those with profound
ventricular dysfunction, however, requires circulatory assistance to permit periprocedural
survival.
Methods: We evaluated the short term safety and efficacy of using Impella left
ventricular assist device in extremely high-risk patient underoing aortic valvulo-
plasty procedure. 13 patients with severe critical aortic stenosis and multiple
co-morbidities underwent BAV at our institute, 53% patients had concomitant
coronary interventions out of which 38% had multivessel PCI . Because of
advanced age, multiple co-morbidities and poor cardiac reserve & hemodynamic
status, the BAV’s were supported with the Impella.We describe a technique in
which a single 14 french retrograde arterial access was obtained and after crossing
the aortic valve, a 0.035 J-wire with LV curve along with a 0.014 Impella wire
was left in the LV cavity. The impella device is primed and loaded on the 0.014
wire ready to go in case of a hemodynamic compromise. After balloon aortic
valvuloplasty with rapid ventricular pacing is done, the Impella LVAD is rapidly
railed into the LV for hemodynamic support.
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